Search alternatives:
ms decrease » _ decrease (Expand Search), mean decrease (Expand Search), use decreased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
n decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
50 n » 50 ns (Expand Search), 50 ng (Expand Search), 50 μ (Expand Search)
ms decrease » _ decrease (Expand Search), mean decrease (Expand Search), use decreased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
n decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
50 n » 50 ns (Expand Search), 50 ng (Expand Search), 50 μ (Expand Search)
-
16641
Data_Sheet_1_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.PDF
Published 2024“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”
-
16642
Table_9_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.DOCX
Published 2024“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”
-
16643
Table_4_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.XLSX
Published 2024“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”
-
16644
Image 3_CS Ratio is an immune-related prognostic biomarker for cervical cancer.tiff
Published 2025“…The CS polarization state reflects a highly coordinated network of pro-tumor anti-tumor variables offering a simplified yet effective immune response indicator for the complex TME. …”
-
16645
Intermittent fasting enhances long-term memory consolidation, adult hippocampal neurogenesis and expression of longevity gene Klotho (Microarray dataset)
Published 2021“…Relatively loose criteria were initially used to filter the data (to minimize analytical false negatives), but genes were required to pass these criteria for each of the four methods to be considered further (four out of four methods) to minimize analytical false positives. </p> <p>A fold change of 1.2 along with a t-test p-value of less than 0.05 was used in RMA and dChip, and a confidence of 50% or higher was used in the Drop Method. …”
-
16646
Image 2_CS Ratio is an immune-related prognostic biomarker for cervical cancer.tiff
Published 2025“…The CS polarization state reflects a highly coordinated network of pro-tumor anti-tumor variables offering a simplified yet effective immune response indicator for the complex TME. …”
-
16647
Image 1_CS Ratio is an immune-related prognostic biomarker for cervical cancer.tiff
Published 2025“…The CS polarization state reflects a highly coordinated network of pro-tumor anti-tumor variables offering a simplified yet effective immune response indicator for the complex TME. …”
-
16648
S1 Data -
Published 2025“…Notably, moderate (D2) and severe (D3) drought treatments led to negative GD values. GD decreased by 23.79%, 114.85%, and 175.50% for D1, D2, and D3 treatments, respectively, while reductions of 40.00%, 73.33%, and 90.00% in GD were observed compared to the control (CK). …”
-
16649
S3 Data -
Published 2025“…Notably, moderate (D2) and severe (D3) drought treatments led to negative GD values. GD decreased by 23.79%, 114.85%, and 175.50% for D1, D2, and D3 treatments, respectively, while reductions of 40.00%, 73.33%, and 90.00% in GD were observed compared to the control (CK). …”
-
16650
S2 Data -
Published 2025“…Notably, moderate (D2) and severe (D3) drought treatments led to negative GD values. GD decreased by 23.79%, 114.85%, and 175.50% for D1, D2, and D3 treatments, respectively, while reductions of 40.00%, 73.33%, and 90.00% in GD were observed compared to the control (CK). …”
-
16651
S5 Data -
Published 2025“…Notably, moderate (D2) and severe (D3) drought treatments led to negative GD values. GD decreased by 23.79%, 114.85%, and 175.50% for D1, D2, and D3 treatments, respectively, while reductions of 40.00%, 73.33%, and 90.00% in GD were observed compared to the control (CK). …”
-
16652
S6 Data -
Published 2025“…Notably, moderate (D2) and severe (D3) drought treatments led to negative GD values. GD decreased by 23.79%, 114.85%, and 175.50% for D1, D2, and D3 treatments, respectively, while reductions of 40.00%, 73.33%, and 90.00% in GD were observed compared to the control (CK). …”
-
16653
S4 Data -
Published 2025“…Notably, moderate (D2) and severe (D3) drought treatments led to negative GD values. GD decreased by 23.79%, 114.85%, and 175.50% for D1, D2, and D3 treatments, respectively, while reductions of 40.00%, 73.33%, and 90.00% in GD were observed compared to the control (CK). …”
-
16654
S7 Data -
Published 2025“…Notably, moderate (D2) and severe (D3) drought treatments led to negative GD values. GD decreased by 23.79%, 114.85%, and 175.50% for D1, D2, and D3 treatments, respectively, while reductions of 40.00%, 73.33%, and 90.00% in GD were observed compared to the control (CK). …”
-
16655
Factors affecting LLINs usage at household level.
Published 2025“…Not owning a bed decreased the likelihood of net usage by 13.3% [aOR=0.867 (95% CI = 0.816–0.920), p < 0.001]. …”
-
16656
Net usage across intervention arms.
Published 2025“…Not owning a bed decreased the likelihood of net usage by 13.3% [aOR=0.867 (95% CI = 0.816–0.920), p < 0.001]. …”
-
16657
Factors associated with malaria infection.
Published 2025“…Not owning a bed decreased the likelihood of net usage by 13.3% [aOR=0.867 (95% CI = 0.816–0.920), p < 0.001]. …”
-
16658
Presentation_1_Transcriptome analysis reveals differences in cell cycle, growth and migration related genes that distinguish fibroblasts derived from pre-invasive and invasive brea...
Published 2023“…Background/Introduction<p>As the most common form of pre-invasive breast cancer, ductal carcinoma in situ (DCIS) affects over 50,000 women in the US annually. Despite standardized treatment involving lumpectomy and radiation therapy, up to 25% of patients with DCIS experience disease recurrence often with invasive ductal carcinoma (IDC), indicating that a subset of patients may be under-treated. …”
-
16659
Synthesis of Bis-β-Diketonate Lanthanide Complexes with an Azobenzene Bridge and Studies of Their Reversible Photo/Thermal Isomerization Properties
Published 2019“…The ligand, bis-β-diketone with an azobenzene bridge (4,4′-(4,4,4-trifluoro-1,3-butanedione)azobenzene, <b>H</b><sub><b>2</b></sub><b>L</b>), was prepared for the synthesis of a series of dinuclear lanthanide complexes with the formula <b>[Ln</b><sub><b>2</b></sub><b>L</b><sub><b>3</b></sub><b>(DMSO)</b><sub><b>4</b></sub><b>]</b> (Ln = Eu<sup>3+</sup>, Gd<sup>3+</sup>, Tb<sup>3+</sup>, and DMSO = dimethyl sulfoxide). …”
-
16660
Synthesis of Bis-β-Diketonate Lanthanide Complexes with an Azobenzene Bridge and Studies of Their Reversible Photo/Thermal Isomerization Properties
Published 2019“…The ligand, bis-β-diketone with an azobenzene bridge (4,4′-(4,4,4-trifluoro-1,3-butanedione)azobenzene, <b>H</b><sub><b>2</b></sub><b>L</b>), was prepared for the synthesis of a series of dinuclear lanthanide complexes with the formula <b>[Ln</b><sub><b>2</b></sub><b>L</b><sub><b>3</b></sub><b>(DMSO)</b><sub><b>4</b></sub><b>]</b> (Ln = Eu<sup>3+</sup>, Gd<sup>3+</sup>, Tb<sup>3+</sup>, and DMSO = dimethyl sulfoxide). …”